Hepatorenal syndrome: an update

Sao Paulo Medical Journal

Tércio Genzini²  Fábio César Miranda Torricelli¹ 

[1] ,HEPATO

关键词: Hepatorenal syndrome;    Renal insufficiency;    Liver cirrhosis;    Portal hypertension;    Vasoconstrictor agents;    Síndrome hepatorrenal;    Insuficiência renal;    Cirrose hepática;    Hipertensão portal;    Agentes vasopressores;   

DOI  :  10.1590/S1516-31802007000100010

来源: SciELO

【 摘 要 】

Hepatorenal syndrome (HRS) is the development of renal failure in patients with chronic previous liver disease, without clinical or laboratory evidence of previous kidney disease. It affects up to 18% of cirrhotic patients with ascites during the first year of follow-up, reaching 39% in five years and presenting a survival of about two weeks after its establishment. HRS diagnosis is based on clinical and laboratory data. The occurrence of this syndrome is related to the mechanism for ascites development, involving vasoconstriction, low renal perfusion, water and sodium retention, increased plasma volume, and consequent overflow at the splanchnic level. Renal vasoactive mediators like endothelin 1, thromboxane A2, and leukotrienes are also involved in the genesis of this syndrome, which culminates in functional renal insufficiency. The treatment of choice can be pharmacological or surgical, although liver transplantation is the only permanent and effective treatment, with a four-year survival rate of up to 60%. Liver function recovery is usually followed by renal failure reversion. Early diagnosis and timely therapeutics can increase life expectancy for these patients while they are waiting for liver transplantation as a definitive treatment.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License